Treatment Trials

2 Clinical Trials for Various Conditions

Focus your search

      RECRUITING
      A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
      Description

      The goal of this open-label dose escalation and expansion study is to evaluate the safety and tolerability of NKT5097 in adults with advanced/metastatic tumors (emphasis on breast cancer and solid tumors with CCNE1 amplification). Main questions to answer include: * What is the recommended dose for expansion and/or Phase 2 * What medical issues/symptoms do participants experience when taking NKT5097

      Conditions
      HR+ Breast CancerTriple Negative Breast Cancer (TNBC)CCNE1 Amplified Advanced Solid TumorsHR+ HER2- Breast CancerOvarian CancerEndometrial CancerUterine Carcinosarcoma
      Talk to us
      RECRUITING
      Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
      Description

      Phase I: Characterize safety and tolerability of ECI830 as a single agent and in combination with ribociclib and fulvestrant. Identify dose range for optimization/recommended dose for future studies. Phase II: Assess the anti-tumor activity of ECI830 in combination with ribociclib and fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer.

      Conditions
      Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid Tumors
      Talk to us